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Abstract
Objective: An animal model has been designed to assess the feasibility of off-pump mitral valve replacement using valved stents. Methods:
Glutaraldehyde-preserved homograft was sutured inside a prosthetic tube (Dacron). Then, two self-expandable nitinol Z-stents were sutured on
the external surface of the prosthesis in such a way to create two self-expanding crowns for fixation. In adult pigs and under general anesthesia,
the left atrium was exposed through a left thoracotomy and atrio-ventricular roadmapping was performed with intravascular ultrasound (IVUS)
and fluoroscopy. The double-crowned valved stents were loaded into a delivery sheath. The sheath was then introduced into the left atrium and
the valved stents was deployed in mitral position in such a way that the part in between the two stents was at the level of the mitral annulus.
Intracardiac Unltrasound (ICUS) was used to assess the valve function. Hemodynamic parameters were gathered as well. Animal survived for no
more than 3 h after the valve deployment and gross anatomy examination of the left heart was carried out. Results: The mean height of the
valved stents was 29.4G0.2 mm, with an internal diameter of 20.4G1.0 mm, and an external diameter of 25.5G0.8 mm. The procedure was
successfully carried out in eight animals. In vivo evaluation showed a native mitral annulus diameter of 24.9G0.6 mm, and a mean mitral valve
area of 421.4G17.5 mm2. ICUS showed a mild mitral regurgitation in three out of eight animals. Mean pressure gradient across the valved stents
was 2.6G3.1 mmHg. Mean pressure gradient across the left ventricular outflow tract (LVOT) was 6.6G5.2 mmHg. The mean survival time was
97.5G56.3 min (survival time range was 40–180 min). One animal died due to the occlusion of the LVOT because of valved stents displacement.
Postmortem evaluation confirmed correct positioning of the valved stent in the mitral position in seven out of eight animals. No atrial or
ventricular lesions due to the valved stents were found. Conclusions: Off-pump implantation of a self-expandable valved stent in the mitral
position is technically feasible. Further studies will assess if this procedure is also feasible in humans.
Q 2005 Elsevier B.V. All rights reserved.
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Since Davies H. deployed a catheter-mounted unicuspid
valve above the aortic valve for the relief of aortic
insufficiency in 1965 [1], much effort has been made to
develop valved stent implantation. Off-bypass implantation
of a valved stent in the pulmonary position is a reality [2].
Aortic valved stent can be successfully implanted without
thoracotomy by using a transluminal catheter technique
[3–7]. Furthermore, percutaneous insertion of pulmonary
valve has also been achieved [8–10].1010-7940/$ - see front matter Q 2005 Elsevier B.V. All rights reserved.
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E-mail address: piergiorgio.tozzi@hospvd.ch (P. Tozzi).Based on our previous experiences on off-pump pulmon-
ary and aortic valved stent implantation [2,11,12], we
decided to verify the feasibility of off-pump implantation
in mitral valve position of a dedicated valved stent. After
extensive bench tests, and inspired by the Ross procedure
[13–15], we choose the aortic and/or pulmonary homograft
as valve of choice.
In this paper, we present the first description and
preliminary results of a new self-expandable artificial
heart valve designed for implantation in the mitral position
without extracorporeal circulation.2. Materials and methods
We designed and made a self-expanding valved stent
specially intended for an atrio-ventricular valve. This valved
stent has a shape that reminds a double opposite crowns.
The groove between the two crowns is placed at the level of
the mitral annulus and should secure the fixation in mitral
position of all the devices.European Journal of Cardio-thoracic Surgery 28 (2005) 194–199www.elsevier.com/locate/ejcts
Fig. 1. The double-crowned valved stent. A porcine pulmonary valve has been
sutured into a Dacron conduit. Then, two self-expandable nitinol Z-stents
were sutured on the external surface of the prosthesis in such a way to create
two self-expanding crowns for fixation.
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preserved aortic and six glutaraldehyde-preserved pulmon-
ary valvular homografts were sutured into a 20 mm diameter
Dacron tube prior to the attachment of two self-expandable
non-thermosensitive nitinol Z-stents at the center of the
device, thus forming two self-expanding crowns for fixation.
(Fig. 1).
The valved stent was then loaded into a custom-made
Teflon sheath stent-graft delivery system with an overall
diameter of 10 mm (Fig. 2).
The endpoint of the study is to asses the feasibility of the
deployment procedure and verify if it can cause severe
hemodynamic instability.
Study design: an acute in vivo evaluation was performed in
eight pigs with a mean body weight of 46.0G4.3 kg (range 43–
56 kg). Under general anesthesia and ECG and blood pressure
monitoring, both internal jugular vein were exposed,
respectively, for infusion and introduction of a Swan–Ganz
catheter. ECG, heart rate, mean blood pressure, cardiac
output and pulmonary artery pressure were recorded before
and 30 min after the valve deployment. The left femoral vein
was exposed for insertion of an intracardiac ultrasonic probe.
A left posterolateral thoracotomy in the fourth inter-
costal space was performed and the pericardium was opened
to reach the left atrium. We marked the atrio-ventricularFig. 2. The self-expanding valved stent loading and half-deploying in a Teflon
sheath stent-graft delivery system.groove with 3–4 clips, at the level of the mitral annulus, thus
regarding it as the valved stent implantation site.
Heparin (100 IU/kg) was administered intravenously. An
intracardiac ultrasonic probe (ICUS) was inserted into the
right atrium through the left femoral vein in order to monitor
our intracardiac manipulations.
Two purse string sutures were made with 6-0 polypropy-
lene thread on the left atrium. The atrium was then
punctured with a needle and a guide wire was inserted into
it before a short 9-F sheath was introduced.
The intravascular ultrasound (IVUS 12.5 MHz,6F, Clearview,
BostonScientificCorporation,Sunnyvale,CA)was then inserted
through the 9-F sheath, in order to measure the diameter and
area of mitral valve. The position of annulus was confirmed as
well under the guidance of fluoroscopy. The IVUS was then
removed to allowed the introduction of the delivery system.
An incision of 1 cm was made on left atrium, controlled by
the purse strings. The custom-made delivery introducer
loaded with the valved stent was pushed along the guide
wire, until the middle of the valved stent reached the mitral
annulus previously marked with metallic clips. The sheath
was pulled back while the piston was held in place, and the
ventricular side of the valved stent was deployed. We gently
pulled the whole introducer to ensure fixation of the valved
stent before deploying the atrial side (Fig. 3).
ICUS (intracardiac ultrasound, Sequoia) was used to asses
valve competence and function. The pressure gradient
between left atrium and ventricle (proximal and distal to
the valved stent) was directly measured with a needle.
The double-crowned valved stent function was assessed
for at least 1 h after the deployment for a maximum of 3 h.
Then, animals were sacrificed in order to check the adequate
position of the valved stents: mitral annulus in between the
two crowned stents.
All the pigs received care in compliance with the
Principles of Laboratory Animals’ formulated by the NationalFig. 3. Delivering the valved stent under the guidance of fluoroscopy. The
custom-made delivery introducer loaded with the valved stent was pushed
along the guide wire, until the middle of the valved stent reached the mitral
annulus previously marked with metallic clips. The sheath was pulled back
while the piston was held in place, and the ventricular side of the valved stent
was deployed. We gently pulled the whole introducer to ensure fixation of the
valved stent before deploying the atrial side.
Table 1
Hemodynamic data before and 30 min after the valved stent deployment
Valved stent deployment
Before 30 min after
ECG Sinus rhythm Sinus rhythm
HR (beats/min) 80G12 83G11
MAP (mmHg) 66G8 69G8
CO (l/min per m2) 3.96G0.8 3.86G0.6
PAP (mmHg) 20G1 20G1
Fig. 5. Postmortem evaluation confirmed good positioning of valved stents in
the mitral position and no left ventricle outflow tract obstruction.
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Use of Laboratory Animals’ prepared by the Institute of
Laboratory Animal Resources and published by the National
Institute of Health (NIH publication 85-23, revised 1985).
The protocol was approved by the Institutional Committee
on Animal Research.
Data were analyzed with SPSS software (Statistical
Package for the Social Sciences). Paired t tests were used.
Values were reported as meanGSD.Table 2
Summary of procedural data
Procedure successfully completed 8 out of 8 animals
Mean procedure time 18G8 min
Valve deployment time !30 s
Native mitral annulus diameter 24.9G0.6 mm
Native mitral valve area 421.4G17 mm23. Results
The mean height of the valved stents was 29.4G0.2 mm,
with an internal diameter of 20.4G1.0 mm, and an external
diameter of 25.5G0.8 mm. The procedure was successfully
completed in all animals. Mean procedure time was 18G
8 min and all valves were deployed in less than 30 s.
Hemodynamic data before and 30 min after valve deploy-
ment are reported in Table 1. In vivo evaluation showed a
native mitral annulus diameter of 24.9G0.6 mm, and a mean
mitral valve area of 421.4G17.5 mm2. Comparatively, they
were 19.8G0.4 mm and 238.5G15.2 mm2, respectively,
after implantation. ICUS confirmed complete valve opening
and closure of the valved stents (Fig. 4) and showed a mild
paravalvular regurgitation in three out of eight animals. In
these animals, there was the highest degree of mismatch
between mitral annulus size and stented valve size: the
annulus diameter was more than 20% bigger than the stented
valve diameter. Mean pressure gradient across the valved
stents was 2.6G3.1 mmHg (range 0–8 mmHg). Mean pressure
gradient across the left ventricular outflow tract (LVOT) was
6.6G5.2 mmHg (range 1–15 mmHg). The mean survival time
was 97.5G56.3 min (survival time range was 40–180 min).
One animal died due to the valve displacement 40 min after
the valve deployment. Mean blood loss during the procedure
was 55G25 cm3. Postmortem evaluation confirmed that the
native mitral annulus was in between the two crowned stents
in seven out of eight animals. In one animal, the valvedFig. 4. ICUS showed a good fixation of the valved stent in the mitral position.stents migrated into the ventricle causing the complete
occlusion of the LVOT. No atrial or ventricular lesions due to
the valved stents were found (Fig. 5). Detailed results are
reported in Tables 2 and 3.4. Discussion
4.1. Valved stents design and deployment
Because of the special anatomy of atrio-ventricular valve,
the valved stent was made up of two systems: a valve system
and a fixation system. The ventricular stent guarantees the
fixation of the device to the mitral annulus, while the atrial
stent holds in place the homograft sutured on the prosthesis.
The two stents are connected in the center of the device to
avoid mutual interference and in such a way to squeeze the
mitral annulus in a sandwich-like technique. We chose
porcine aortic or pulmonary valves as they were easily
obtainable and easily sutured into a 20 mm diameter Dacron
tube graft. The graft acts like an external support to the
homograft, preventing its collapse during manipulation and
after deployment.Double-crowned valved stents diameter 19.8G4 mm
Double-crowned valved stents area 238.5G15.2 mm2
Blood loss during procedure 55G25 cm3
Complication One late valve displacement
Table 3
Echocardiography assessment of double-crowned valved stents in mitral
position
Pressure gradient across the valve 2.6G3.1 mmHg
Pressure gradient across the LVOT 6.6G5.2 mmHg
Mild mitral regurgitation 3 out of 8 animals
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but, since we deployed the valve from the left atrium, the
sheath diameter was not a big concern. The introducer was
cut to 25–30 cm in length for easy manipulation, and its tip
was kept short (!2 cm), due to space restriction in the left
ventricle.
The valved stents were unloaded from the introducer
system following a double stages procedure. The ventricular
stent was deployed first under fluoroscopic control, by
pulling the sheath. During this phase we could still adjust the
position and direction of the valved stents in order to have
the native mitral annulus, represented by the metallic clips,
exactly in between the ventricular and atrial stent. Then the
atrial stent was deployed, by pulling the sheath. This
approach increased the successful rate of deployments.
The endpoint of this study was to evaluate the feasibility
of the off-pump implantation of the self-made valved stent
in the mitral position. In our short-term experiment, the
duration of deployment was about 15–20 s and no significant
hemodynamic changes were noted probably because the
deployment was too quick to impair left ventricular
function. All the implanted valved worked properly as the
two-dimensional echocardiography has shown, and there
were no significant changes in the hemodynamic parameters
after the valve deployment (Table 1). However, in three
animals we detected a mild paravalvular regurgitation due
to the mismatch between native annulus and valve size: the
annulus diameter was more than 20% bigger than the stented
valve diameter. This problem was difficult to overcome just
because we had a limited number of homograft available;
therefore, choosing the right valve for the right annulus size
was not always easy. In the next future, a wider selection of
sizes will minimize the number of paravalvular leeks. In one
animal, valve displacement occurred 40 min after its
deployment causing sudden occlusion of the LVOT and the
death of the animal. Once again, we believe the dislodgment
of the valve occurred because it was undersized with respect
of annulus diameter. Postmortem evaluation confirmed the
good positioning of seven out of eight valved stents in the
mitral position with the mitral annulus squeezed in between
atrial and ventricular stents.
This preliminary study shows the feasibility of an off-
pump implantation of the valved stent in the mitral position,
which could be used as part of the treatment for patients
with mitral regurgitation who are not candidates for open
heart surgery, such as those with severe heart failure as well
as hepatic and renal function failure. Also, patients with
mitral stenosis could be eligible for this treatment after
percutaneous dilatation of the mitral stenosis. Implantation
of valved stents may protect the left ventricular function
from severe regurgitation, even temporarily. The morbidity
of reoperation might decrease after alleviation of left heart
dysfunction by implantation of a valved stent.
4.2. Study limitations
Left ventricleoutflowtract (LVOT)obstruction is oneof the
main drawback of this technique even if, in this study, the
gradient across the LVOT was quite low, thanks to the
particular geometry of the pig’s left ventricle: mitral and
aortic valves lie almost on the same plane. We believe that inthe human normal heart, the ventricular portion of the valved
stents canprotrude into the left ventricle in such a way topush
the anterior leaflet of the mitral valve towards the LVOT,
miming a SAM (systolic anterior movement) effect. Moreover,
the subvalvular apparatus is displaced as well and could
significantly contribute to the LVOT obstruction. In order to
prevent this potential complication, we are now working on a
second generation of valved stent that has the ventricular
stent shorter than the first one and with a asymmetric shape.
All these concerns regarding the potential LVOT obstruction
are, somehow, lukewarm because patients with mitral valve
regurgitation have often dilated left ventricle and this
condition should minimize the risk of anterior displacement
of the mitral leaflet. However, there is always the possibility
to incise the anterior leaflet by robotic surgery in working
heart before implantation, if necessary [16].
Because only an acute study was performed, the long-
term durability and stability of the valved stents are
unknown.
However, all the catheter-delivered valved stents have
been intended for temporary, not long-term placement and
use. Our experiment also focused on short-term testing at
present.
In conclusion, off-pump implantation of a self-expand-
able valved stent in the mitral position is technically
feasible. Further studies will assess if this procedure is also
feasible in humans.Acknowledgements
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Dr J. Revuelta (Santander, Spain): I have a technical question. In case
that you will apply this clinically in patients, do you think that this device
could be implanted through the apex with a small incision or through the
intercostal groove, also with a small mini thoracotomy in the intercostal
space? Are you planning to do that or just to leave it for cardiologists?
Dr Tozzi: If the question is who can do this procedure, cardiologist or
surgeon, I think that anyone that can handle a hole in the left atrium without
compromising his own coronary flow or his cardiac flow can do this procedure.
So, in other words, this is so far a procedure that has to be done by a cardiac
surgeon, because you have to do a hole in the left atrium or, if you want, in the
left ventricle, but it is a surgical approach.
Dr Revuelta: But you are in favor of inter-atrial groove? There is no
problem, no coronaries there, no nothing?
Dr Tozzi: No. It is not possible in the inter-atrial groove.
Dr Revuelta: So you think it would be the best way?
Dr Tozzi: It will be possible, yes, with a small incision, exactly as we do in
the animal.
Dr Revuelta: With thoracoscopy you can see?
Dr Tozzi: Theoretically it is feasible. We have a few technical problems,
but theoretically it is feasible to do this with a thoracoscopy with a minimally
invasive approach, absolutely.
think those are indications for repair and not replacement.
So I am not yet clear as to your projection as to what would be the
indications specifically for replacement in this group of patients.
Dr Tozzi: What I didn’t say is that the paravalvular leakage is due to a
mismatch between the shape and the diameter of the mitral annulus versus
the diameter and the shape of the stent. We are working on that. We are
trying to create a valved stent in order to be much more flexible in order to
adapt itself to the geometry of the mitral annulus.
Of course, on the other hand, we will have the problem of stented valve
stability, because a very compliant valve is also a very unstable valve, so far.
But this is a technical issue. I am sure there are several bioengineers that are
able to give a very good answer to this problem. So I think we can overcome
this technical issue. But up to now this is a problem.
Dr Shennib: The indications, which group of patients would you
recommend this as you mature it?
Dr Tozzi: So far, as I said, mitral regurgitation, any kind of mitral
regurgitation, theoretically there won’t be any problem to deploy a valve such
as this one. Of course, a patient with mitral stenosis due to a severe
calcification of the mitral annulus, we could have more problems. But once
again, I think those problems can be overcome with technical modifications.
So it is just a technical issue.
Dr F. Mohr (Leipzig, Germany): I think it is extremely interesting. Did you
look at other stent designs, valve designs which more or less mimic the mitral
valve, because you just used the rounded shape of the aortic valve design? Did
you try this, yes or no?
Dr Tozzi: Yes, yes, absolutely.Appendix B. Editorial Comment
Off-pump mitral valve replacement: an attack on conven-
tional heart surgery?
Georg Lutter*, Jochen Cremer
Department of Cardiovascular Surgery,
University of Kiel, School of Medicine,
24105 Kiel, Germany
The pioneering introduction of the Starr–Edwards valve
allowed complete replacement of the diseased mitral valve.With improved cardiopulmonary bypass, myocardial protec-
tion, and surgical techniques the mortality rate associated
with mitral valve replacement decreased. Augmented use of
mitral valve repair techniques has resulted in a substantial
decrease in long-term morbidity and mortality when treating
patients with mitral regurgitation. Some believed that this
resulted from maintaining continuity of the mitral annular
papillary muscle continuity during mitral valve repair.
Additional studies have validated the positive long-term
effects of maintaining the integrity of the mitral valve
subvalvular apparatus [1]. Although surgical approaches to
reduce mitral regurgitation associated with congestive heart
failure have been reported, the high mortality rate that
